Gilead agreed to buy biotech company Myogen for $2.5 Billion - is the deal worth?
Paula Scott
Oct. 2, 2006

Ambrisentan is the main profitable drug of Myogen. Is it worth $52.50 a share?

Gilead agreed to buy biotech company Myogen for $2.5 Billion - is the deal worth?

Myogen is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders. We believe that our advanced understanding of the biology of cardiovascular disease combined with our clinical development expertise in cardiovascular therapeutics provide us with the capability to discover novel therapies, as well as identify, license or acquire products that address serious, debilitating cardiovascular disorders that are not adequately treated with existing therapies.

We have two product candidates in late-stage clinical development: ambrisentan for the treatment of pulmonary arterial hypertension (PAH) and darusentan for the treatment of resistant hypertension (RHTN). Myogen, in partnership with Novartis, also conducts a target and drug discovery research program focused on the development of disease-modifying drugs for the treatment of chronic heart failure and related cardiovascular disorders.

As part of a global PAH collaboration with GlaxoSmithKline (GSK), Myogen has assumed responsibility for the marketing and distribution of GSK's Flolan (epoprostenol sodium) in the United States. Myogen launched commercial operations in Q2 2006.

Gilead agreed to buy biotech company Myogen for $2.5 Billion - is the deal worth?
Paula Scott
Ambrisentan is the main profitable drug of Myogen. Is it worth $52.50 a share?
READ MORE>>

Apollo Management and Texas Pacific Group plan to buy Harrah's for $81 per share - what does this signal for the market?
Sam Adelton
This will create the biggest leveraged buy out in the history - another sign of market topping out.
READ MORE>>

WalMart disappoints but construction spending better than expected
Peter Oberois
The economy has a liitle cheer left as construction spending was down only 0.3% while the market was expecting a fall of 1.8%
READ MORE>>

Banks trying to snatch each others top-paid traders and investment bankers - Morgan Stanley starts offering millions of dollars worth of incentives to keep the best
Peter Oberois
Millions of dollars are being offered as incentive to stay and not defect. Even larger sums are being offered to defect as signing bonuses.
READ MORE>>

It may be the right time to take your fixed rate 15 or 30 year mortgage - bond rally may be over
Karen Gonzales
As commodity prices trend to shoot up again, bond yeilds will go up, The worst for the bond market can come with the slightest hint that the economy is accelerating again.
READ MORE>>

Commodity traders positioning themselves for rallies in gold, copper and oil as China gets ready for the next round of solid buying
Bob Grasso
China needs oil, copper and gold. These commodities may have bottomed according to some analysts and commodity traders. They are buy these futures with some hedges.
READ MORE>>

MORE ARTICLES >>